

Brian C Case

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/170203/publications.pdf>

Version: 2024-02-01

97
papers

776
citations

687220

13
h-index

642610

23
g-index

98
all docs

98
docs citations

98
times ranked

871
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug-Coated Balloon for De Novo Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1061-1073.	1.2	96
2	Initial Findings From the North American COVID-19 Myocardial Infarction Registry. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1994-2003.	1.2	96
3	COVID-19 (SARS-CoV-2) and the Heart – An Ominous Association. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 946-949.	0.3	41
4	Risk of Coronary Obstruction and Feasibility of Coronary Access After Repeat Transcatheter Aortic Valve Replacement With the Self-Expanding Evolut Valve. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009496.	1.4	38
5	Transcatheter Versus Surgical Aortic Valve Replacement in Young, Low-Risk Patients With Severe Aortic Stenosis. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1169-1180.	1.1	30
6	Micropuncture technique for femoral access is associated with lower vascular complications compared to standard needle. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1379-1385.	0.7	28
7	Comparison of Characteristics and Outcomes of Patients With Acute Myocardial Infarction With Versus Without Coronarvirus-19. <i>American Journal of Cardiology</i> , 2021, 144, 8-12.	0.7	25
8	Treatment of ST-Segment Elevation Myocardial Infarction During COVID-19 Pandemic. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1024-1029.	0.3	20
9	Bioresorbable Scaffolds: Current Technology and Future Perspectives. <i>Rambam Maimonides Medical Journal</i> , 2020, 11, e0016.	0.4	19
10	Admissions Rate and Timing of Revascularization in the United States in Patients With Non-ST-Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2020, 134, 24-31.	0.7	17
11	Tip-to-Base LAMPOON for Transcatheter Mitral Valve Replacement With a Protected Mitral Annulus. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 541-550.	1.1	17
12	LAMPOON techniques to prevent or manage left ventricular outflow tract obstruction in transcatheter mitral valve replacement. <i>Annals of Cardiothoracic Surgery</i> , 2021, 10, 172-179.	0.6	16
13	Lifetime management of patients with symptomatic severe aortic stenosis: a computed tomography simulation study. <i>EuroIntervention</i> , 2022, 18, e407-e416.	1.4	15
14	Real-World Experience of the Sentinel Cerebral Protection Device: Insights From the FDA Manufacturer and User Facility Device Experience (MAUDE) Database. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 235-238.	0.3	14
15	Tip-to-Base LAMPOON to Prevent Left Ventricular Outflow Tract Obstruction in Valve-in-Valve Transcatheter Mitral Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1126-1128.	1.1	12
16	Reasons for Screen Failure for Transcatheter Mitral Valve Repair and Replacement. <i>American Journal of Cardiology</i> , 2021, 148, 130-137.	0.7	12
17	Guidelines for Balancing Priorities in Structural Heart Disease During the COVID-19 Pandemic. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1030-1033.	0.3	11
18	The Orsiro Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stent: A Review of Current Evidence. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 540-548.	0.3	11

#	ARTICLE	IF	CITATIONS
19	<scp>Realâ€world</scp> experience of <scp>sutureâ€based</scp> closure devices: Insights from the <scp>FDA</scp> Manufacturer and User Facility Device Experience. Catheterization and Cardiovascular Interventions, 2021, 98, 572-577.	0.7	11
20	Clinical Impact and Predictors of Troponin Elevation in Patients With COVID-19. Cardiovascular Revascularization Medicine, 2021, 33, 41-44.	0.3	11
21	<scp>Propensityâ€matched</scp> comparison of <scp>largeâ€bore</scp> access closure in transcatheter aortic valve replacement using <scp>MANTA</scp> versus Perclose: A <scp>realâ€world</scp> experience. Catheterization and Cardiovascular Interventions, 2021, 98, 580-585.	0.7	11
22	Waksman In-Stent Restenosis Classification: A Mechanism-Based Approach to the Treatment of Restenosis. Cardiovascular Revascularization Medicine, 2021, 33, 62-67.	0.3	11
23	The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy. Journal of Clinical Lipidology, 2019, 13, 754-761.	0.6	10
24	Feasibility and Safety of High-Risk Percutaneous Coronary Intervention Without Mechanical Circulatory Support. Circulation: Cardiovascular Interventions, 2021, 14, e009960.	1.4	10
25	Procedural Outcomes of Patients Undergoing Percutaneous Coronary Intervention for De Novo Lesions in the Ostial and Proximal Left Circumflex Coronary Artery. American Journal of Cardiology, 2020, 135, 62-67.	0.7	9
26	Intravascular Lithotripsy Facilitated Percutaneous Endovascular Intervention of the Aortic Arch: A Single-Center Experience. Cardiovascular Revascularization Medicine, 2020, 21, 1006-1015.	0.3	9
27	Pre-Operative Cardiovascular Testing and Post-Renal Transplant Clinical Outcomes. Cardiovascular Revascularization Medicine, 2019, 20, 588-593.	0.3	8
28	Intravascular ultrasound guidance in the evaluation and treatment of left main coronary artery disease. International Journal of Cardiology, 2021, 325, 168-175.	0.8	8
29	National trends and 30-day readmission rates for next-day-discharge transcatheter aortic valve replacement: An analysis from the Nationwide Readmissions Database, 2012-2016. American Heart Journal, 2021, 231, 25-31.	1.2	8
30	Optimizing Monotherapy Selection, Aspirin Versus P2Y12 Inhibitors, Following Percutaneous Coronary Intervention. American Journal of Cardiology, 2020, 135, 154-165.	0.7	7
31	MitraClip 30-Day Readmissions and Impact of Early Discharge: An Analysis from the Nationwide Readmissions Database 2016. Cardiovascular Revascularization Medicine, 2020, 21, 954-958.	0.3	7
32	Balloon-Expandable Valve Geometry After Transcatheter Aortic Valve Replacement in Low-Risk Patients With Bicuspid Versus Tricuspid Aortic Stenosis. Cardiovascular Revascularization Medicine, 2021, 33, 7-12.	0.3	7
33	The Impact of Aortic Angulation on Contemporary Transcatheter Aortic Valve Replacement Outcomes. JACC: Cardiovascular Interventions, 2021, 14, 1209-1215.	1.1	7
34	Transcatheter Aortic Valve Replacement in Low-Risk Bicuspid and Tricuspid Patients: Meta-Analysis. Cardiovascular Revascularization Medicine, 2021, 33, 1-6.	0.3	6
35	Impact of Left Ventricular Outflow Tract Calcification on Outcomes Following Transcatheter Aortic Valve Replacement. Cardiovascular Revascularization Medicine, 2022, 35, 1-7.	0.3	6
36	Overview of the FDA's Circulatory System Devices Panel virtual meeting on the TransMedics Organ Care System (OCS) Heart â€ portable extracorporeal heart perfusion and monitoring system. American Heart Journal, 2022, 247, 90-99.	1.2	6

#	ARTICLE	IF	CITATIONS
37	Postoperative myocardial injury and outcomes in liver and kidney transplant patients. <i>Cardiovascular Revascularization Medicine</i> , 2022, , .	0.3	6
38	Safety and Feasibility of Performing Pericardiocentesis on Patients with Significant Pulmonary Hypertension. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 1090-1095.	0.3	5
39	Real-World Experience of the MANTA Closure Device: Insights From the FDA Manufacturer and User Facility Device Experience (MAUDE) Database. <i>Cardiovascular Revascularization Medicine</i> , 2021, 27, 63-66.	0.3	5
40	Meta-Analysis of Usefulness of Antiplatelet Therapy in Ischemic Stroke or Transient Ischemic Attack. <i>American Journal of Cardiology</i> , 2021, 153, 129-134.	0.7	5
41	Implications of Left Ventricular Function on Short-Term Outcomes in COVID-19 Patients With Myocardial Injury. <i>Cardiovascular Revascularization Medicine</i> , 2021, 29, 45-49.	0.3	5
42	Evolution of Management and Outcomes of Patients with Myocardial Injury During the COVID-19 Pandemic. <i>American Journal of Cardiology</i> , 2021, 157, 42-47.	0.7	5
43	Adverse Events and Modes of Failure Related to Rotational Atherectomy System: The Utility of the MAUDE Database. <i>Cardiovascular Revascularization Medicine</i> , 2021, 27, 57-62.	0.3	4
44	Utility of Routine Invasive Coronary Angiography Prior to Transcatheter Aortic Valve Replacement. <i>Cardiovascular Revascularization Medicine</i> , 2021, 26, 1-5.	0.3	4
45	Comparison of Outcomes in Patients With COVID-19 and Thrombosis Versus Those Without Thrombosis. <i>American Journal of Cardiology</i> , 2021, 160, 106-111.	0.7	4
46	Prosthetic valve endocarditis after transcatheter aortic valve replacement in <sc>lowâ€risk</sc> patients. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 896-903.	0.7	4
47	Shared Decision Making in Cardiovascular Disease in the Outpatient Setting. <i>JACC: Case Reports</i> , 2019, 1, 261-270.	0.3	3
48	Treatment of a Heavily Calcified Celiac Artery Ostial Subtotal Occlusion Using Shockwave Lithotripsy: A Novel Approach. <i>Cardiovascular Revascularization Medicine</i> , 2021, 25, 72-74.	0.3	3
49	The challenges of coronary noâ€reflow phenomenon. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 612-613.	0.7	3
50	Overview of the Virtual 2021 FDAâ€™s Circulatory System Devices Advisory Panel on Lutonix 014 Drug-Coated Percutaneous Transluminal Angioplasty Catheter for Below-the-Knee Lesions in Critical Limb Ischemia. <i>Cardiovascular Revascularization Medicine</i> , 2021, 33, 55-61.	0.3	3
51	Pre-Operative Cardiovascular Testing before Liver Transplantation. <i>American Journal of Cardiology</i> , 2021, 152, 132-137.	0.7	3
52	One-Year Outcomes After Treatment of Ostial In-Stent Restenosis in Left Circumflex Versus Left Anterior Descending or Right Coronary Artery. <i>American Journal of Cardiology</i> , 2021, 151, 45-50.	0.7	3
53	Single-Center Experience With the LOTUS Edge Transcatheter Heart Valve. <i>Cardiovascular Revascularization Medicine</i> , 2021, 29, 85-88.	0.3	3
54	Contemporary postâ€marketing adverse events and modes of failure related to VASCADE Vascular Closure System: The utility of the MAUDE database. <i>Catheterization and Cardiovascular Interventions</i> , 2021, , .	0.7	3

#	ARTICLE	IF	CITATIONS
55	Overview of FDA Circulatory System Devices Panel virtual meeting on TriGUARD 3 cerebral embolic protection. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 1789-1795.	0.7	3
56	Implications of COVID-19 Vaccination on Hospital Encounters and Outcomes. <i>American Journal of Cardiology</i> , 2022, 170, 105-111.	0.7	3
57	Sex Disparities in Hemodynamics and Outcomes in Patients Who Underwent Contemporary Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2022, 174, 101-106.	0.7	3
58	Pulmonary Embolism Diagnosed From Right Heart Changes Seen After Exercise Stress Echocardiography. <i>Circulation: Cardiovascular Imaging</i> , 2015, 8, e003506.	1.3	2
59	Review of Structural Late-Breaking Trials From the TVT Connect 2020 and PCR e-Course 2020 Virtual Meetings. <i>Cardiovascular Revascularization Medicine</i> , 2021, 27, 71-78.	0.3	2
60	Pericardiocentesis induced right ventricular changes in patients with and without pulmonary hypertension. <i>Echocardiography</i> , 2021, 38, 752-759.	0.3	2
61	Cangrelor vs. glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. <i>American Heart Journal</i> , 2021, 238, 59-65.	1.2	2
62	Non-ST-Segment Elevation Myocardial Infarction: When Is Rapid Revascularization Critical?. <i>Journal of the American Heart Association</i> , 2021, 10, e023645.	1.6	2
63	Valve-in-Valve for Failing Mitral Bioprosthesis With Tip-to-Base LAMPOON to Prevent Left Ventricular Outflow Tract Obstruction. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2021, 16, 409-413.	0.4	2
64	Lipid-rich plaque density and low-density lipoprotein cholesterol in statin-treated versus statin-naïve patients: a post hoc analysis of the LRP study. <i>EuroIntervention</i> , 2022, 18, 91-93.	1.4	2
65	Procedural Characteristics and Outcomes of Patients Undergoing Percutaneous Coronary Intervention During Normal Work Hours Versus Non-work Hours. <i>American Journal of Cardiology</i> , 2020, 135, 32-39.	0.7	1
66	Review of CRT 2020 Late-breaking Trials. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 707-711.	0.3	1
67	Review of ACC 2020 Late-Breaking Trials in Interventional Cardiology. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 905-911.	0.3	1
68	Treatment of Patients With Recurrent Coronary In-stent Restenosis With Failed Intravascular Brachytherapy. <i>American Journal of Cardiology</i> , 2021, 142, 44-51.	0.7	1
69	Optical Coherence Tomography based treatment approach for patients with Acute Coronary Syndrome. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 141-149.	0.6	1
70	Right transradial coronary angiography in the setting of tortuous brachiocephalic/thoracic aorta (â€œelephant headâ€œ): Impact on fluoroscopy time and contrast use. <i>Catheterization and Cardiovascular Interventions</i> , 2021, , .	0.7	1
71	A patient-level, pooled analysis of mortality rates with the Paseo-18 Lux paclitaxel drug-coated balloon in peripheral arterial disease. <i>Cardiovascular Revascularization Medicine</i> , 2021, 33, 49-54.	0.3	1
72	The impact of COVID-19 patients with troponin elevation on renal impairment and clinical outcome. <i>Cardiovascular Revascularization Medicine</i> , 2021, 33, 45-48.	0.3	1

#	ARTICLE	IF	CITATIONS
73	High-Risk Percutaneous Coronary Intervention of Native Coronary Arteries Without Mechanical Circulatory Support in Acute Coronary Syndrome Without Cardiogenic Shock. American Journal of Cardiology, 2021, 158, 37-44.	0.7	1
74	Impact of Left Ventricular Outflow Tract Calcium on Hemodynamics and Outcomes in Patients After Transcatheter Aortic Valve Implantation With a Contemporary Self-Expanding Valve. American Journal of Cardiology, 2022, 168, 128-134.	0.7	1
75	Impact of baseline imaging of non-culprit coronary lesions and adverse events: Insight from LRP study. Cardiovascular Revascularization Medicine, 2021, , .	0.3	1
76	The Need for Additional Phenotyping When Defining Cardiogenic Shock. JACC: Cardiovascular Interventions, 2022, 15, 890-895.	1.1	1
77	Comparison of coronary revascularization appropriateness for non-acute coronary syndrome cases under the 2017 update vs the 2012 appropriate use criteria. Catheterization and Cardiovascular Interventions, 2019, 93, 620-625.	0.7	0
78	Resolution of Massive Intracoronary Thrombus During Percutaneous Coronary Intervention Utilizing Intensive Pharmacological and Aspiration Strategies. Cardiovascular Revascularization Medicine, 2020, 21, 251-253.	0.3	0
79	One Valve Type Does Not Fit All. Cardiovascular Revascularization Medicine, 2020, 21, 931.	0.3	0
80	Risk of Mortality with Paclitaxel Drug-Coated Balloon in De Novo Coronary Artery Disease. Cardiovascular Revascularization Medicine, 2020, 21, 549-555.	0.3	0
81	Review of PCR e-Course 2020 Late-Breaking Clinical Trials. Cardiovascular Revascularization Medicine, 2021, 27, 67-70.	0.3	0
82	Cases of Early, Aggressive In-Stent Restenosis in Left Main Double Kissing (DK) Crush Technique and Treatment Options. Cardiovascular Revascularization Medicine, 2021, 27, 90-94.	0.3	0
83	Return of the Left Internal Mammary Artery. Cardiovascular Revascularization Medicine, 2021, 23, 119-120.	0.3	0
84	Intravascular Lithotripsy-Facilitated Carotid Interventions. Journal of Endovascular Therapy, 2021, 28, 486-486.	0.8	0
85	Rescue alcohol septal ablation for dynamic left ventricular outflow tract obstruction and haemodynamic collapse after transcatheter aortic valve implantation. European Heart Journal, 2021, 42, 2955.	1.0	0
86	Usefulness of Antiplatelet Therapy After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2021, 149, 57-63.	0.7	0
87	Review of Imaging and Physiology Late Breaking Trials From the TCT Connect 2020 Virtual Meeting. Cardiovascular Revascularization Medicine, 2021, 28, 71-75.	0.3	0
88	Review of Structural Late Breaking Trials From the TCT Connect 2020 Virtual Meeting. Cardiovascular Revascularization Medicine, 2021, 28, 76-81.	0.3	0
89	Review of Late-Breaking Trials From CRT 2021 Virtual. Cardiovascular Revascularization Medicine, 2021, 28, 3-8.	0.3	0
90	Review of Coronary Late Breaking Trials From the TCT Connect 2020 Virtual Meeting. Cardiovascular Revascularization Medicine, 2021, 28, 65-70.	0.3	0

#	ARTICLE	IF	CITATIONS
91	Complications of Late-Presenting Myocardial Infarction in a COVID-19 Patient. <i>Cardiovascular Revascularization Medicine</i> , 2021, 29, 100-101.	0.3	0
92	Review of Interventional Late Breaking Trials From AHA Scientific Sessions 2020 Virtual Meeting. <i>Cardiovascular Revascularization Medicine</i> , 2021, 29, 71-76.	0.3	0
93	Early Leaflet Thickening, Durability and Bioprosthetic Valve Failure in TAVR. <i>Interventional Cardiology Clinics</i> , 2021, 10, 531-539.	0.2	0
94	Severe ischemic cardiomyopathyâ€”a new answer in management?. <i>Annals of Translational Medicine</i> , 2016, 4, S46-S46.	0.7	0
95	Exploiting the Transformation Temperature to Reform an Infolded Nitinol Self-Expanding Peripheral Stent. <i>Journal of Endovascular Therapy</i> , 2022, , 152660282110687.	0.8	0
96	COVID-19 pandemic and acute myocardial infarction: Don't ignore chest pain. <i>Cardiovascular Revascularization Medicine</i> , 2022, , .	0.3	0
97	Usefulness of Temporary Pacing in Patients With New Left Bundle Branch Block During Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2022, , .	0.7	0